Arcutis Biotherapeutics, Inc.
Simbol: ARQT
NASDAQ
8.02
USDTržna cena danes
-2.8364
Razmerje P/E
0.0000
Razmerje PEG
926.51M
Kapaciteta MRK
- 0.00%
Donos DIV
Arcutis Biotherapeutics, Inc. (ARQT) Finančni izkazi
Bilanca stanja
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1100.97 | 272.8 | 409.6 | 387.1 | |||||||
balance-sheet.row.short-term-investments | 717.66 | 183.5 | 355.9 | 290.6 | |||||||
balance-sheet.row.net-receivables | 75.2 | 25.8 | 8.5 | 0.4 | |||||||
balance-sheet.row.inventory | 46.07 | 13.1 | 7.5 | 1.2 | |||||||
balance-sheet.row.other-current-assets | 63.5 | 18.7 | 10.6 | 14.2 | |||||||
balance-sheet.row.total-current-assets | 1288.52 | 330.4 | 437.4 | 402.8 | |||||||
balance-sheet.row.property-plant-equipment-net | 17.21 | 3.9 | 4.6 | 5.3 | |||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.intangible-assets | 26.88 | 6.4 | 7.2 | 0 | |||||||
balance-sheet.row.goodwill-and-intangible-assets | 26.88 | 6.4 | 7.2 | 0 | |||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.other-non-current-assets | 1.87 | 0.6 | 0.1 | 0.1 | |||||||
balance-sheet.row.total-non-current-assets | 45.95 | 10.9 | 11.9 | 5.4 | |||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-assets | 1334.47 | 341.4 | 449.3 | 408.2 | |||||||
balance-sheet.row.account-payables | 54.81 | 12 | 8.8 | 7.4 | |||||||
balance-sheet.row.short-term-debt | 2.82 | 0.7 | 0.7 | 0.4 | |||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.long-term-debt-total | 812.38 | 201.8 | 201.9 | 77.1 | |||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||
balance-sheet.row.other-current-liab | 104.61 | 33.9 | 28.3 | 25.5 | |||||||
balance-sheet.row.total-non-current-liabilities | 816.61 | 206 | 201.9 | 77.1 | |||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.capital-lease-obligations | 16.73 | 3.4 | 4.8 | 5.2 | |||||||
balance-sheet.row.total-liab | 978.85 | 252.7 | 239.7 | 110.5 | |||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.common-stock | 0.03 | 0 | 0 | 0 | |||||||
balance-sheet.row.retained-earnings | -3568.24 | -981.9 | -719.8 | -408.3 | |||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -0.89 | 0 | -1.1 | -0.3 | |||||||
balance-sheet.row.other-total-stockholders-equity | 3924.73 | 1070.6 | 930.4 | 706.2 | |||||||
balance-sheet.row.total-stockholders-equity | 355.62 | 88.7 | 209.6 | 297.7 | |||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 1334.47 | 341.4 | 449.3 | 408.2 | |||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-equity | 355.62 | 88.7 | 209.6 | 297.7 | |||||||
balance-sheet.row.total-liabilities-and-total-equity | 1334.47 | - | - | - | |||||||
Total Investments | 717.66 | 183.5 | 355.9 | 290.6 | |||||||
balance-sheet.row.total-debt | 818.58 | 205.9 | 202.5 | 77.6 | |||||||
balance-sheet.row.net-debt | 435.26 | 116.6 | 148.9 | -18.9 |
Izkaz denarnih tokov
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -262.14 | -262.1 | -311.5 | -206.4 | |||||||
cash-flows.row.depreciation-and-amortization | 1.52 | 1.9 | 0.9 | 0.5 | |||||||
cash-flows.row.deferred-income-tax | -19.69 | 19.8 | 0 | 3.5 | |||||||
cash-flows.row.stock-based-compensation | 38.81 | 38.8 | 32.7 | 23.9 | |||||||
cash-flows.row.change-in-working-capital | -23.5 | -23.5 | -10.2 | 3.6 | |||||||
cash-flows.row.account-receivables | -17.35 | -17.3 | -8.5 | 0 | |||||||
cash-flows.row.inventory | -5.62 | -5.6 | -7.5 | 0 | |||||||
cash-flows.row.account-payables | 3.15 | 3.2 | 1.6 | 0.2 | |||||||
cash-flows.row.other-working-capital | -3.68 | -3.7 | 4.2 | 3.4 | |||||||
cash-flows.row.other-non-cash-items | 17.94 | -21.9 | 30.3 | 0.3 | |||||||
cash-flows.row.net-cash-provided-by-operating-activities | -247.06 | 0 | 0 | 0 | |||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.43 | -0.4 | -23.3 | -1 | |||||||
cash-flows.row.acquisitions-net | -180.66 | 0 | 22.9 | 75 | |||||||
cash-flows.row.purchases-of-investments | -225.84 | -225.8 | -415.4 | -292.5 | |||||||
cash-flows.row.sales-maturities-of-investments | 406.5 | 406.5 | 351.5 | 217.6 | |||||||
cash-flows.row.other-investing-activites | 180.66 | 0 | -22.9 | -75 | |||||||
cash-flows.row.net-cash-used-for-investing-activites | 180.23 | 180.2 | -87.2 | -76 | |||||||
cash-flows.row.debt-repayment | 0 | 0 | -122.8 | -72.3 | |||||||
cash-flows.row.common-stock-issued | 100.26 | 101.3 | 176 | 207.5 | |||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 12.5 | 0.8 | |||||||
cash-flows.row.dividends-paid | 0 | 0 | -122.8 | -72.3 | |||||||
cash-flows.row.other-financing-activites | 101.32 | 5.6 | 358.9 | 218.3 | |||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 101.32 | 101.3 | 301.8 | 281.9 | |||||||
cash-flows.row.effect-of-forex-changes-on-cash | -0.05 | -0.1 | 0 | 0 | |||||||
cash-flows.row.net-change-in-cash | 34.45 | 34.4 | -43.1 | 31.4 | |||||||
cash-flows.row.cash-at-end-of-period | 386.09 | 89.3 | 54.9 | 98 | |||||||
cash-flows.row.cash-at-beginning-of-period | 351.64 | 54.9 | 98 | 66.6 | |||||||
cash-flows.row.operating-cash-flow | -247.06 | -247.1 | -257.7 | -174.6 | |||||||
cash-flows.row.capital-expenditure | -0.43 | -0.4 | -23.3 | -1 | |||||||
cash-flows.row.free-cash-flow | -247.49 | -247.5 | -281 | -175.6 |
Vrstica izkaza poslovnega izida
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 59.61 | 59.6 | 3.7 | 0 | |||||||
income-statement-row.row.cost-of-revenue | 5.18 | 6.1 | 0.8 | 0.8 | |||||||
income-statement-row.row.gross-profit | 54.42 | 53.5 | 2.9 | -0.8 | |||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.research-development | 110.58 | - | - | - | |||||||
income-statement-row.row.selling-general-administrative | 235.81 | - | - | - | |||||||
income-statement-row.row.selling-and-marketing-expenses | -50.87 | - | - | - | |||||||
income-statement-row.row.other-expenses | 11.72 | 11.8 | 5.8 | 0.2 | |||||||
income-statement-row.row.operating-expenses | 295.52 | 294.6 | 304.6 | 206.5 | |||||||
income-statement-row.row.cost-and-expenses | 300.71 | 300.7 | 305.3 | 206.5 | |||||||
income-statement-row.row.interest-income | 12.9 | 0 | 9.8 | 0.2 | |||||||
income-statement-row.row.interest-expense | 29.71 | 29.7 | 15.7 | 0 | |||||||
income-statement-row.row.selling-and-marketing-expenses | -50.87 | - | - | - | |||||||
income-statement-row.row.total-other-income-expensenet | -3.08 | -17.9 | -9.8 | 0.2 | |||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||
income-statement-row.row.other-operating-expenses | 11.72 | 11.8 | 5.8 | 0.2 | |||||||
income-statement-row.row.total-operating-expenses | -3.08 | -17.9 | -9.8 | 0.2 | |||||||
income-statement-row.row.interest-expense | 29.71 | 29.7 | 15.7 | 0 | |||||||
income-statement-row.row.depreciation-and-amortization | 6.7 | 1.9 | 5.8 | 0.5 | |||||||
income-statement-row.row.ebitda-caps | -231.67 | - | - | - | |||||||
income-statement-row.row.operating-income | -241.1 | -241.1 | -301.6 | -206.5 | |||||||
income-statement-row.row.income-before-tax | -259.09 | -259 | -311.5 | -206.4 | |||||||
income-statement-row.row.income-tax-expense | 12.77 | 3.1 | 9.8 | -0.5 | |||||||
income-statement-row.row.net-income | -261.78 | -262.1 | -321.3 | -205.9 |
Pogosto zastavljeno vprašanje
Kaj je Arcutis Biotherapeutics, Inc. (ARQT) skupna sredstva?
Arcutis Biotherapeutics, Inc. (ARQT) skupna sredstva so 341365000.000.
Kakšen je letni prihodek podjetja?
Letni prihodki so 51635000.000.
Kolikšna je stopnja dobička podjetja?
Dobiček podjetja je 0.913.
Kakšen je prosti denarni tok podjetja?
Prosti denarni tok je -2.673.
Kolikšna je neto stopnja dobička podjetja?
Čista stopnja dobička je -4.392.
Kolikšni so skupni prihodki podjetja?
Celotni prihodki so -4.045.
Kaj je Arcutis Biotherapeutics, Inc. (ARQT) čisti dobiček (čisti dobiček)?
Čisti dobiček (čisti prihodek) je -262140000.000.
Kolikšen je skupni dolg podjetja?
Skupni dolg je 205916000.000.
Kolikšni so stroški poslovanja?
Stroški poslovanja so 294589000.000.
Kolikšno je število denarnih sredstev podjetja?
Denarna sredstva podjetja so 89323000.000.